EP0954307A1 - Emploi de 3,4-diphenyl chromans dans des preparations pharmaceutiques inhibant un ou plusieurs symptomes du syndrome premenstruel - Google Patents

Emploi de 3,4-diphenyl chromans dans des preparations pharmaceutiques inhibant un ou plusieurs symptomes du syndrome premenstruel

Info

Publication number
EP0954307A1
EP0954307A1 EP97930359A EP97930359A EP0954307A1 EP 0954307 A1 EP0954307 A1 EP 0954307A1 EP 97930359 A EP97930359 A EP 97930359A EP 97930359 A EP97930359 A EP 97930359A EP 0954307 A1 EP0954307 A1 EP 0954307A1
Authority
EP
European Patent Office
Prior art keywords
use according
anyone
compound
symptoms
premenstrual syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97930359A
Other languages
German (de)
English (en)
Inventor
Birgitte Hjort Guldhammer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0954307A1 publication Critical patent/EP0954307A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Definitions

  • 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome.
  • the present invention relates to the use of compounds of the general formula I for the inhibition of one or more symptoms of premenstrual syndrome.
  • the present invention also embraces pharmaceutical compositions comprising these compounds and methods of using the compounds and their pharmaceutical compositions.
  • PMS Premenstrual syndrome
  • the symptoms that occur can be both physical and psychological in nature. Irritability, snappiness and being on a "short fuse", depression and aggression are the most common reported psychological symptoms, but tension and anxiety are also frequent. Other psychological and behavioural symptoms which have been suggested to occur during the premenstrual phase and menstruation include, for example, decreased efficiency, insomnia, confusion, poorer judgement, difficulty in concentrating, crying, loneliness, restlessness, irritability, and mood swings. The effect of these symptoms can be compounded by physical symptoms which wary widely. The most common reported symptoms are tiredness, a feeling of abdominal bloating and breast swelling, and weight gain.
  • symptoms which have been suggested to occur include, for example, dizziness, faintness, cold sweats, nausea, vomiting, hot flashes, muscle stiffness, headache, cramps, backache, general aches and pains, and water retention including, for example, weight gain, skin disorders, painful breasts, and swelling.
  • treatments have been suggested for alleviating or minimising symptoms of premenstrual syndrome. These include, for example, non-pharmaceutical therapy such as variation in total energy intake and consumption of protein, fat, carbohydrates, vitamin B 6 and E, as well as e.g. supplements of magnesium or calcium and Evening primrose oil containing gamolenic acid.
  • Non-hormonal therapy such as treatment with serotonin re-uptake inhibitors and hormonal therapy such as treatment with progesterone and progestogens, combined oral contraceptives, oestrogen replacement therapy, danazol and gonadotrophin hormone agonists.
  • hormonal therapy such as treatment with progesterone and progestogens, combined oral contraceptives, oestrogen replacement therapy, danazol and gonadotrophin hormone agonists.
  • Centchroman is a non-steroidal compound known to have antiestrogenic activity. It is in use in India as an oral contraceptive (see, for example, Salman si aj., U.S. Patent Specification No. 4,447,622; Singh si aj., Acta Endocrinal (Copenh) 123. (1992), 444 - 450; Grubb, Curr Opin Obstet Gynecol 3.
  • Centchroman has also been in- vestigated as an anti-cancer agent for treatment of advanced breast cancer (Misra si al., Int J Cancer 42 (1989), 781 - 783). Recently, centchroman as a racemate has been found as a potent cholesterol lowering pharmaceutical expressed by a significant decrease of the serum concentrations (S.D. Bain si al-, J Min Bon Res S (1994), S 394).
  • U.S. Patent No. 5,453,442 describes methods of lowering serum cholesterol and inhibiting smoother muscle cell proliferation in humans and inhibiting uterine fibroid disease and endometriosis in women by administering compounds of formula I as shown therein.
  • US Patent No. 5,280,040 describes methods and pharmaceutical compositions for reducing bone loss using 3,4-diaryl chro ans and their pharmaceutically acceptable salts. There is no disclosure in the patents of using the compounds to treat or alleviate pre- menstrual syndrome.
  • One object of the present invention is to provide compounds which can be used in alleviating one or more of the symptoms associated with premenstrual syndrome.
  • the present invention provides the use of compounds of the general formula I
  • R 1 , R 4 and R 5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C,. 6 alkyl, C-. 6 alkoxy or (tertiary amino)( C,. 6 alkoxy); and R 2 and R 3 are individually hydrogen or C, ⁇ alkyl, or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome.
  • the present invention is based on the discovery that a group of 3,4-diarylchromans of for- mula I are useful for alleviating one or more of the symptoms associated with premenstrual syndrome.
  • the present invention provides the use of a compound of the general formula I
  • R 1 , R 4 and R 5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R 2 and R 3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment of premenstrual syndrome.
  • the present invention provides a method of inhibiting one or more symptoms of premenstrual syndrome comprising administering to a subject in need of treatment an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
  • inhibitor is defined to include its generally accepted meaning which includes, for example, prophylactically treating a female human subject from incurring the symptoms of PMS, holding in check each symptom, alleviating one or more symptoms and/or treating existing symptoms.
  • the present method includes both medical treatment and /or prophylactic treatment, as appropriate.
  • R 1 , R 4 and R 5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, C-. 6 alkyl, C,. 6 alkoxy or (tertiary amino)( C,. 6 alkoxy); and R 2 and R 3 are individually hydrogen or a C-. 6 alkyl.
  • lower alkyl includes straight and branched chain alkyl radicals containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-amyl, sec-amyl, n-hexyl, 2-ethylbutyl, 2,3-dimethylbutyl and the like.
  • lower alkoxy includes straight and branched chain alkoxy radicals containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n- amyloxy, sec-amyloxy, n-hexyloxy, 2-ethylbutoxy, 2,3-dimethylbutoxy and the like.
  • Halogen includes chloro, fluoro, bromo and iodo.
  • (tertiary amino)(lower alkoxy) is a lower alkoxy group which is substituted by a tertiary amino radical.
  • the tertiary amino radical may be a N,N-dialkylamine such as a N,N-dimethylamino, N,N-diethylamino, N,N- dipropylamino and N,N-dibutylamino or a polymethyleneimine, e.g., piperidine, pyrrolidine, N-methylpiperazine or morpholine.
  • Preferred compounds include those in which R 1 is lower alkoxy; R 2 and R 3 are lower alkyl, especially methyl; R 4 is hydrogen; and R 5 is (tertiary amino)( lower alkoxy) of the polymethyleneimine type.
  • R-* is in the 7-position and is lower alkoxy, particularly methoxy; each of R 2 and
  • R 3 is methyl
  • R 4 is hydrogen
  • R ⁇ is in the 4-position and is a (tertiary amino)( lower alk- oxy) radical such as 2-(pyrrolidin-1-yl)ethoxy.
  • Preferred compounds include those in which
  • R 1 is C,. 6 alkoxy; R 2 and R 3 are C,. 6 alkyl, especially methyl; R 4 is hydrogen; and R 5 is (tertiary aminoXC ⁇ alkoxy) of the polymethyleneimine type.
  • R 1 is in the 7-position and is C,. 6 alkoxy- particularly methoxy; each of R 2 and
  • R 3 is methyl
  • R 4 is hydrogen
  • R ⁇ is in the 4-position and is a (tertiary amino) ⁇ , ⁇ alkoxy) radical such as 2-(pyrrolidin-1-yl)ethoxy with formula II
  • the compounds of formula I in the transconfiguration. These compounds may be used as racemic mixtures, or the isolated d- or I- enantiomers may be used. The trans-l-enantiomers are more preferred.
  • a particularly preferred compound for use within the present invention is centchroman having the formula IV
  • 3,4-diarylchromans are prepared according to known methods, such as those disclosed in U.S. Patent Specification No. 3,340,276 to Carney ⁇ i aj., U.S. Patent Specification No. 3,822,287 to Bolger, and Ray ⁇ i aj., J Med Chem 13 (1976), 276 - 279, the contents of which are incorporated herein by reference. Conversion of the cis isomer to the trans con- figuration by means of an organometallic base-catalyzed rearrangement is disclosed in U.S. Patent Specification No. 3,822,287.
  • the optically active d- and l-enantiomers may be prepared as disclosed by Salman si aj. in U.S.
  • Patent Specification No. 4,447,622 (incorporated herein by reference) by forming an optically active acid salt which is subjected to alkaline hy- drolysis to produce the desired enantiomer. If R 2 is different from R 3 and R 4 is different from R 5 , the general formula I covers 8 optical isomers.
  • 3,4-diarylchromans of formula I may be prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids.
  • salts include salts of organic acids such as formic acid, fumaric acid, maleic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like.
  • Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like.
  • the acid addition salts may be obtained as the direct products of compound synthesis.
  • the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
  • a preferable salt is the hydrogen fumarate salt.
  • 3,4-diarylchromans of formula I and their salts are useful within human and veterinary medicine, for example, in the treatment of patients suffering from premenstrual syn- drome.
  • 3,4-diarylchromans of formula I and their pharmaceutically acceptable salts are formulated with a pharmaceutically acceptable carrier to provide a medicament for parenteral, oral, nasal, rectal, subdermal or intradermal or trans- dermal administration according to conventional methods.
  • Formulations may further include one or more diluents, fillers, emulsifiers, preservatives, buffers, excipients, etc.
  • the present invention further provides a pharmaceutical composition for alleviating one or more of the symptoms of premenstrual syndrome comprising a compound of formula I and at least one pharmaceutical agent selected from the group consisting of an analgesic, a diuretic, and an antihistamine, in combination with a pharmaceutically acceptable carrier, diluent or excipient.
  • Oral administration is preferred.
  • the active compound of formula I is prepared in a form suitable for oral administration, such as a tablet or capsule.
  • a pharmaceutically acceptable salt of the compound of formula I is combined with a carrier and moulded into a tablet.
  • Suitable carriers in this regard include starch, sugars, dicalcium phos- phate, calcium stearate, magnesium stearate and the like.
  • Such compositions may further include one or more auxiliary substances, such as wetting agents, emulsifiers, preservatives, stabilizers, colouring additives, etc.
  • compositions containing a compound of formula I may be administered one or more times per day or week.
  • An effective amount of such a pharmaceutical composition is the amount that provides a clinically significant effect against premenstrual syndrome. Such amounts will depend, in part, on the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art.
  • a typical daily dose will contain a non-toxic dosage range of from about 0.001 to about 75 mg/kg patient per day of a compound of the present invention, preferably in a range from about 0.01 to 75, more preferably in the range from about 0.01 to 50 mg/kg patient per day.
  • the pharmaceutical compositions containing a compound of formula I may be administered in unit dosage form one or more times per day or week.
  • Implants are formulated to provide release of active compound over the desired period of time, which can be up to several years.
  • Controlled-release formulations are disclosed by, for example, Sanders si aj., J Pharm Sci 73 (1964), 1294 - 1297, 1984; U.S. Patent Specification No. 4,489,056; and U.S. Patent Specification No. 4,210,644, which are incorporated herein by reference.
  • Examples of preferred compounds of formula I are centchroman as a racemic mixture and as isolated l-centchroman and d-centchroman enantiomers. Furthermore, 3,4-trans- 2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl-7-hydroxychroman is a preferred compound. The more preferred compound is isolated l-centchroman (l-3,4-trans-2,2- dimethyl-3-phenyl-4-[4-(2-pyrrolidin-1-yl)ethoxy)phenyl]-7-methoxychroman).
  • Examples of pharmaceutically acceptable acid addition salts are salts with non-toxic acids, either inorganic acids such as hydrochloric acid, sulphuric acid and phosphoric acid, or organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, citric acid, ascorbic acid, benzoic acid, embonic acid, metha- nesulphonic acid and malonic acid.
  • inorganic acids such as hydrochloric acid, sulphuric acid and phosphoric acid
  • organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, citric acid, ascorbic acid, benzoic acid, embonic acid, metha- nesulphonic acid and malonic acid.
  • a clinical case-control study is performed in six to fifty women.
  • the women are in good general health and have regular menstruation, but suffer from PMS as defined above. Symp- toms are reported by questionnaires.
  • the women are divided into two groups, a test group which receives the active compound of this invention, and a control group which receives a placebo. Women in the test group receives between 1 and 500 mg of the test compound orally per day for one to six months. Regularly throughout the study symptoms are carefully recorded and the effects on the symptoms associated with PMS are compared both between the groups and for each patient also with the symptoms reported before treatment began. Effects on any of the symptoms of PMS of the test compound are considered as positive.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

L'invention porte sur de nouvelles utilisations de composés de formule générale (I) dans laquelle R?1, R4 et R5¿ sont individuellement hydrogène, hydroxy, halogène, trifluorométhyle, C¿1-6? alkyle, C1-6 alkoxy, ou (amino tertiaire) (C1-6 alkoxy); et R?2 et R3¿ sont individuellement H ou C¿1-6? alkyle, ou de leurs sels pharmacocompatibles entrant dans la compositions de préparations pharmaceutiques inhibant un ou plusieurs symptômes du syndrome prémenstruel.
EP97930359A 1996-07-12 1997-07-07 Emploi de 3,4-diphenyl chromans dans des preparations pharmaceutiques inhibant un ou plusieurs symptomes du syndrome premenstruel Withdrawn EP0954307A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK78496 1996-07-12
DK78496 1996-07-12
PCT/DK1997/000302 WO1998002154A1 (fr) 1996-07-12 1997-07-07 Emploi de 3,4-diphenyl chromans dans des preparations pharmaceutiques inhibant un ou plusieurs symptomes du syndrome premenstruel

Publications (1)

Publication Number Publication Date
EP0954307A1 true EP0954307A1 (fr) 1999-11-10

Family

ID=8097523

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97930359A Withdrawn EP0954307A1 (fr) 1996-07-12 1997-07-07 Emploi de 3,4-diphenyl chromans dans des preparations pharmaceutiques inhibant un ou plusieurs symptomes du syndrome premenstruel

Country Status (5)

Country Link
EP (1) EP0954307A1 (fr)
JP (1) JP2000514441A (fr)
AU (1) AU3433797A (fr)
WO (1) WO1998002154A1 (fr)
ZA (1) ZA976171B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
CA2581316C (fr) 2004-09-21 2013-09-10 Novogen Research Pty Ltd Derives de chromane substitues, medicaments et utilisation a des fins therapeutiques
EP2635273B1 (fr) 2010-11-01 2020-01-08 MEI Pharma, Inc. Compositions d'isoflavonoïdes et méthodes de traitement du cancer
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9802154A1 *

Also Published As

Publication number Publication date
WO1998002154A1 (fr) 1998-01-22
AU3433797A (en) 1998-02-09
ZA976171B (en) 1998-01-12
JP2000514441A (ja) 2000-10-31

Similar Documents

Publication Publication Date Title
AU693628B2 (en) Use of 3,4-diphenylchromans
US5726202A (en) Benign prostatic hypertrophy
US5883118A (en) Prostatic carcinoma
US5747059A (en) Atrophy of skin/mucous membrane
JP2000506505A (ja) 閉経期の症状の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
US5756539A (en) 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US6008242A (en) Use of 1-centchroman for the manufacture of a pharmaceutical composition for the treatment of obesity
EP0954307A1 (fr) Emploi de 3,4-diphenyl chromans dans des preparations pharmaceutiques inhibant un ou plusieurs symptomes du syndrome premenstruel
WO1998033499A1 (fr) Utilisation de chromanes de 3,4-diphenyle pour la fabrication d'une composition pharmaceutique destinee a augmenter la libido chez les femmes en phase de post-menopause
US5886021A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
WO1998033500A1 (fr) Utilisation de chromanes de 3,4-diphenyle pour la fabrication d'une composition pharmaceutique destinee a inhiber l'insuffisance motrice associee a la senescence
WO1998032437A1 (fr) Utilisation de 3, 4-diphenyle chromanes pour preparer une composition pharmaceutique servant a inhiber une ou plusieurs maladies psychiatriques
CN1207038A (zh) 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
KR19980701383A (ko) 부인병 질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia)
MXPA97005378A (en) Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of the obesi
HK1078778A (en) Use of reboxetine for the treatment of hot flashes
MXPA97005219A (en) Use of 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment of profilaxis of disorders ginecologi

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19991203